

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known	
Application Number			10/505,376	
Filing Date			August 20, 2004	
First Named Inventor			KALLED	
Art Unit			Not Yet Assigned	
Examiner Name			Not Yet Assigned	
Attorney Docket Number			08201.0028-00000	
Sheet	1	of	9	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initial ¹	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/D.K./		5,595,721	01/21/1997	Kaminski et al.	
		5,969,102	10/19/1999	Bram et al.	
		6,297,367	10/02/2001	Tribouley	
		6,316,222	11/13/2001	Bram et al.	
		6,403,770	06/11/2002	Yu et al.	
		6,475,986	11/05/2002	Aggarwal	
		6,541,224	04/01/2003	Yu et al.	
		6,475,987	11/05/2002	Shu	
		6,623,941	09/23/2003	Ruben et al.	
		6,689,579	02/10/2004	Yu et al.	
		6,869,605	03/22/2005	Browning et al.	
		US-2001-0010925	08/02/2001	Wiley	
		US-2002-0037852	03/28/2002	Browning et al.	
		US-2002-0004587	01/10/2002	Miller et al.	
		US-2002-0055624	05/09/2002	Wiley	
		US-2002-0064829	05/30/2002	Yu et al.	
		US-2002-0115112	08/22/2002	Yu et al.	
		US-2002-0165156A1	11/07/2002	Browning et al.	
		US-2002-0172674A1	11/21/2002	Jeffrey et al.	
		US-2003-0022239	01/30/2003	Baker et al.	
		US-2003-0023038	01/30/2003	Rennert	

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	9	Attorney Docket Number	08201.0028-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initial ¹	Cite No.	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/D.K./		US-2003-0053984	03/20/2003	Tschopp et al.	
		US-2003-0082175	05/01/2003	Schneider et al.	
		US-2003-0095967	05/23/2003	MacKay et al.	
		US-2003-0119149	06/26/2003	Reddy	
		US-2003-0148445	08/07/2003	Shu	
		US-2003-0166546	09/24/2003	Aggarwal	
		US-2003-0175208	09/18/2003	Yu et al.	
		US-2003-0194743	10/16/2003	Beltzer et al.	
		US-2003-0211509	11/13/2003	Wiley	
		US-2003-0100068	05/29/2003	Lam et al.	
		US-2003-0100074	05/29/2003	Yu et al.	
		US-2003-0108992	06/12/2003	Lenardo et al.	
		US-2003-0148454	08/07/2003	Marshak-Rothstein et al.	
		US-2003-0166864	09/04/2003	Yu et al.	
		US-2003-0194745	10/16/2003	McDowell et al.	
		US-2003-0198640	10/23/2003	Yu et al.	
		US-2004-0013674	01/22/2004	Ambrose et al.	
		US-2004-0072188	04/15/2004	Ambrose et al.	
		US-2004-0028658	02/12/2004	Faustman	
		US-2004-0033511	02/19/2004	Pfizenmaier et al.	

IDS Form PTO/IB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	9	Attorney Docket Number	08201.0028-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initial*	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/D.K./		US-2004-0038349	02/26/2004	Hilbert et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/D.K./		EP 0 869 180	06/09/1999	SmithKline Beecham Corp.		
/D.K./		EP 0 921 194	06/09/1999	Eli Lilly & Co.		
/D.K./		EP 1 146 892	08/20/2003	Biogen Inc. et al.		
/D.K./		WO 97/33902	09/18/1997	Human Genome Sciences		
/D.K./		WO 98/18921	05/07/1998	Human Genome Sciences		
/D.K./		WO 98/27114	06/25/1998	Schering Corp.		
/D.K./		WO 98/39361	09/11/1998	The Children's Hospital		
/D.K./		WO 98/55620	12/10/1998	Regeneron Pharmaceuticals, Inc.		
/D.K./		WO 98/55621	12/10/1998	Regeneron Pharmaceuticals, Inc.		
/D.K./		WO 99/04001	01/28/1999	Zymogenetics, Inc.		
/D.K./		WO 99/11791	03/11/1999	University of Washington		
/D.K./		WO 99/12964	03/18/1999	Biogen Inc.		
/D.K./		WO 99/12965	03/18/1999	Biogen Inc.		
/D.K./		WO 99/26463	06/03/1999	Eli Lilly & Co.		
/D.K./		WO 99/33980	07/08/1999	Chiron Corp.		
/D.K./		WO 00/26244	05/11/2000	Government of U.S.A. et al.		

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/505,376
				<i>Filing Date</i>	August 20, 2004
				<i>First Named Inventor</i>	KALLED
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	4	of	9	<i>Attorney Docket Number</i>	08201.0028-00000

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number* Kind Code ² (if known)				
/D.K./		WO 00/39295	07/06/2000	Glaxo Group Limited		
/D.K./		WO 00/40716	07/13/2000	Zymogenetics, Inc.		
/D.K./		WO 00/43032	07/27/2000	Biogen Inc.		
/D.K./		WO 00/45836	08/10/2000	Research Development Foundation		
/D.K./		WO 00/47740	08/17/2000	Amgen Inc.		
/D.K./		WO 00/50597	08/31/2000	Human Genome Sciences		
/D.K./		WO 00/50633	08/31/2000	The General Hospital Corp.		
/D.K./		WO 00/60079	10/12/2000	Chiron Corp.		
/D.K./		WO 00/68378	11/16/2000	National Jewish Medical and Research Center		
/D.K./		WO 00/77256	12/21/2000	Human Genome Sciences		
/D.K./		WO 01/40466	06/07/2001	Genetech, Inc.		
/D.K./		WO 01/42298	06/14/2001	Kornbluth		
/D.K./		WO 01/49318	07/12/2001	TR Associates L.L.C.		
/D.K./		WO 01/58949	08/16/2001	Biogen, Inc.		
/D.K./		WO 01/90304	11/29/2001	Human Genome Sciences		
/D.K./		WO 01/96528	12/20/2001	Human Genome Sciences		
/D.K./		WO 02/02641	01/10/2002	Human Genome Sciences et al.		
/D.K./		WO 02/092620	11/21/2002	Amgen, Inc.		
/D.K./		WO 02/15930	02/28/2002	Duke University		

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	9	Attorney Docket Number	08201.0028-00000

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation Yes or No
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/D.K./		WO 02/18620	03/07/2002	Human Genome Sciences		
/D.K./		WO 02/08284	01/31/2002	Genentech, Inc.		
/D.K./		WO 02/38766	05/16/2002	Zymogenetics		
/D.K./		WO 03/001877	01/09/2003	Gene Logic, Inc.		
/D.K./		WO 03/014294	02/20/2003	Genentech, Inc.		
/D.K./		WO 03/022877	03/20/2003	Biogen Inc.		
/D.K./		WO 03/024991	03/27/2003	Amgen Inc.		
/D.K./		WO 03/033658	04/24/2003	Human Genome Sciences		
/D.K./		WO 03/035846	05/01/2003	National Jewish Medical and Research Center		
/D.K./		WO 03/040307	05/15/2003	Human Genome Sciences		
/D.K./		WO 03/050134	06/19/2003	Human Genome Sciences		
/D.K./		WO 03/055979	07/10/2003	Human Genome Sciences		
/D.K./		WO 03/060071	07/24/2003	Human Genome Sciences et al.		
/D.K./		WO 03/060072	07/24/2003	Immunex Corp.		
/D.K./		WO 04/016737	02/26/2004	Eli Lilly and Company		
/D.K./		WO 04/035735	04/29/2004	Genentech, Inc.		
/D.K./		WO 05/005462	01/20/2005	Genentech, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-------------------	-----------------------	--

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	08201.0028-00000
Sheet	6	of	9		

NON PATENT LITERATURE DOCUMENTS

/D.K./		International Search Report, International Application No. PCT/US00/01788.
/D.K./		Colman P.M., "Effects of amino acid sequence changes on antibody-antigen interaction," 55 th Forum in Immunol., pgs. 33-36 (1994)
/D.K./		Dang et al., "SLE-Like Autoantibodies and Sjögren's Syndrome-Like Lymphoproliferation in TGF- β Knockout Mice," <i>J. Immunol.</i> , 155:3205-3212 (1995)
/D.K./		Do et al., "Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response," <i>J. Exp. Med.</i> 192(7):953-964 (2000)
/D.K./		EMBL Database entry, ID No. AA682496. 10 December 1997
/D.K./		EMBL Database entry, ID No. H58828. 22 April 1995
/D.K./		Furie et al., "Safety, Pharmacokinetic and Pharmacodynamic Results of a Phase 1 Single and Double Dose-Escalation Study of LymphoStat-B in SLE Patients," American College of Rheumatology (ACR), 67 th Annual Scientific meeting, Abstract. 922 (Oct. 23-28, 2003)
/D.K./		Gallagher et al., "A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF- α antibody afelimomab in patients with sepsis syndrome," <i>Intensive Care Med.</i> , 27:1169-1178 (2001)
/D.K./		GenBank Accession No. AK008142, Published February 16, 2001 8 Feb 2001
/D.K./		Gordon et al., "BAFF/Blys Receptor 3 Comprises a Minimal TNF Receptor-Like Module that Encodes a Highly Focused Ligand-Binding Site," <i>Biochemistry</i> 42:5977-5983 (2003)
/D.K./		Gras et al., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes," <i>Intl. Immunol.</i> , 7:1093-1106 (1995)
/D.K./		Gross et al., "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease," <i>Nature</i> , 404:995-999 (2000)
/D.K./		Hahne et al., "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," <i>J. Exp. Med.</i> , 188:1185-1190 (1998)
/D.K./		Harlow E. and Lane D., Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory Press, pgs. 141-155 (1988)
/D.K./		Kalled et al., "BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders," <i>Expert. Opin. Ther. Targets</i> , 7(1):115-123 (2003)
/D.K./		Kashii et al., "CONSTITUTIVE EXPRESSION AND ROLE OF THE TNF FAMILY LIGANDS IN APOPTOTIC KILLING OF TUMOR CELLS BY HUMAN NK CELLS," <i>J. Immunol.</i> , 163:5358-66 (2003)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/505,376
				<i>Filing Date</i>	August 20, 2004
				<i>First Named Inventor</i>	KALLED
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
				<i>Attorney Docket Number</i>	08201.0028-00000
Sheet	7	of	9		

NON PATENT LITERATURE DOCUMENTS

/D.K./		Kayagaki et al, "BAFF/BlyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF- κ B2," <i>Immunity</i> , Vol. 10, 17(4):515-524 (2002)
/D.K./		Khare et al, "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice," <i>PNAS USA</i> , 97:3370-3375 (2000)
/D.K./		Khare et al., "The role of TALL-1 and APRIL in immune regulations," <i>Trends Immunol.</i> 22(2):61-63 (2001)
/D.K./		Kogan et al, "A Single Amino Acid Residue Can Determine the Ligand Specificity of E-selectin," <i>J. Biol. Chem.</i> , 270(23):14047-55 (1995)
/D.K./		Kwon et al, "Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes," <i>Curr. Opinion in Immunol.</i> , 340-345 (1999)
/D.K./		Laabi et al, "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma," <i>EMBO J.</i> , 11:3897-3904 (1992)
/D.K./		Laabi et al, "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed," <i>Nucleic Acids Res.</i> , 22:1147-1154 (1994)
/D.K./		Mackay et al, "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations," <i>J. Exp. Med.</i> , 190:1697-1710 (1999)
/D.K./		Mackay, F. and Ambrose, C., "The TNF family members BAFF and APRIL: the growing complexity," <i>Cytokine & Growth Factor Reviews</i> , 14:311-324 (2003)
/D.K./		Madry et al, "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily," <i>Intl. Immunol.</i> , 10:1693-1702 (1998)
/D.K./		Marietta et al, "The level of BlyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome," <i>Ann Rheum Dis.</i> , 62:168-171 (2003)
/D.K./		Moore et al, "BLYS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator," <i>Science</i> , 285:260-263 (1999)
/D.K./		Mukhopadhyay et al, "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor- κ B, and c-Jun NH ₂ -Terminal Kinase," <i>J. Biol. Chem.</i> , 274:15978-15981 (1999)
/D.K./		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>Birkhauser</i> , ch. 14:491-494 (1994)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/505,376
				Filing Date	August 20, 2004
				First Named Inventor	KALLED
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	08201.0028-00000
Sheet	8	of	9		

NON PATENT LITERATURE DOCUMENTS

/D.K./		Parry et al, "Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice," <i>Journ. Pharm. Exp. Ther.</i> , 296(2):396-404 (2001)
/D.K./		Pitti et al, "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer," <i>Nature</i> , 396:699-703 (1998)
/D.K./		Schneider et al, "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth," <i>J. Exp. Med.</i> , 189:1747-1756 (1999)
/D.K./		Shu, H.B. and Johnson, H, "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1," <i>PNAS USA</i> , 97:9156-9161 (1999)
/D.K./		Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens," <i>J. Leukocyte Biol.</i> 65:680-683 (1999)
/D.K./		Stump et al, "Human Genome Sciences Initiates Trial of a New Drug for Systemic Lupus Erythematosus and Other Autoimmune Diseases," <i>HGS Press Release</i> , pgs. 1-4 and <i>Human Genome Sciences Product Guides</i> , pgs. 1-9 and pgs. 1-13 (Nov. 2001)
/D.K./		Thompson et al, "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population," <i>J. Exp. Med.</i> , 192:129-135 (2000)
/D.K./		Thompson et al, "BAFF interacts with the orphan receptor, BCMA," <i>Scandinavian J. of Immunol., Abstract</i> , 65 (2000)
/D.K./		Thompson, J.S. et al. "BAFF-R, A Newly Identified TNF Receptor That Specifically Interacts with BAFF," <i>Science</i> 293:2108-211 (2001)
/D.K./		Von Bülow et al, "Regulation of the T-Independent Humoral Response by TACI," <i>Immunity</i> , 14:573-582 (2001)
/D.K./		Ward PA and Mulligan MS, "Blocking of adhesion molecules <i>in vivo</i> as anti-inflammatory therapy," <i>Ther Immunol</i> , 1:165-171 (1994)
/D.K./		Ware CF, "APRIL and BAFF Connect Autoimmunity and Cancer," <i>J Exp Med.</i> , 192(11):F35-37 (2000)
/D.K./	Halpern-Wendy	Halpern-Wendy et al, "Effects of LymphoStat-B, a BlyS Antagonist, when Administered Intravenously to Cynomolgus Monkeys," American College of Rheumatology (ACR), 67 th Annual Scientific meeting, Abstract, 1537 (Oct. 23-28, 2003)
/D.K./		Wu et al., "Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI is a High Affinity Receptor of TNF Family Members APRIL and BlyS," <i>J. Biol. Chem.</i> 275(45):35478-35485 (2000)

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Application Number</i>	10/505,376
				<i>Filing Date</i>	August 20, 2004
				<i>First Named Inventor</i>	KALLED
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
Sheet	9	of	9	<i>Attorney Docket Number</i>	08201.0028-00000

NON PATENT LITERATURE DOCUMENTS

/D.K./		Xia et al, "TACI is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> , 192:137-143 (2000)
/D.K./		Yan, M. et. al, "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency," <i>Curr. Biol.</i> 11:1547-1552 (2001)
/D.K./		Yu et al, "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nat. Immun.</i> , 1:252-256 (2000)
Examiner /Daniel Kolker/		Date Considered 01/13/2009
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		